Shinichi Tamu­ra re­claims the throne at So­sei; Jeff Abbey ex­its Ar­gos for No­vadip; Frank Cz­er­wiec is the new CMO at Goldfinch

→ Jeff Abbey is jump­ing to the helm of Bel­gium’s No­vadip Bio­sciences af­ter lead­ing Ar­gos Ther­a­peu­tics as pres­i­dent and CEO for the past eight years. Hav­ing led No­vadip’s au­tol­o­gous cell ther­a­py through a Phase I/IIa tri­al in spinal fu­sion pa­tients, found­ing CEO Jean-François Pol­let de­cid­ed it’s time to pass the reins to a more ex­pe­ri­enced chief ex­ec­u­tive. And Abbey — whose ex­pe­ri­ence in­cludes over­see­ing a Phase III tri­al, rais­ing over $250 mil­lion in pri­vate fi­nanc­ings and an IPO, and seal­ing sev­er­al part­ner­ships — fits the bill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER